A study on treatment outcomes in MDR-TB patients on long term regimen in West Godavari district

Gedela Vasavi, Banerji Neerugatti, Chiranjeevi Uday Kumar, Hari Jagannadha Rao


Background: MDR-TB is defined as a TB patient whose biological specimen is resistant to isoniazid and rifampicin with or without resistant to other first line drugs, based on results from quality assured laboratory. The main aim of this study was to study the treatment outcomes of longer regimen for MDR-TB patients.

Methods: This is a retrospective observational cohort study. After obtaining ethical committee approval from Institutional ethics committee, data was collected from district TB centre from 2011-2016. Outcomes of a regimen is measured in terms of cured, treatment completed, number of defaulters, treatment failure, number of patients shifted to XDR-TB regimen, number of patients died for patients on longer regimen of MDR-TB. The collected data was entered in Microsoft excel 2007 and analysed using SPSS version 20 software.

Results: Out of 211 patients, 167 were males and 44 were females. The total numbers of patients registered from rural areas were 123 and from urban areas were 88. The association between geographical distribution and treatment outcome was measured using Chi-square test and X2=12.1026, p=0.0005 which was significant. Out of 211 patients registered, 87 (41.2%) were cured of disease, 55 (26%) died, 2 (0.9%) patients shifted to XDR. 18 (8.5%) patients were defined as defaulters and 2 (0.9%) patients were defined as treatment failures.

Conclusions: Our study findings have indicated that treatment outcomes in drug resistant TB may be influenced by rural and urban distribution.


MDR-TB, XDR-TB, Treatment outcomes

Full Text:



Revised National tuberculosis control programme, National strategic plan for tuberculosis elimination 2017–2025. Available at: WriteReadData/NSP%20Draft%2020.02.2017%201.pdf. Accessed on 20 September 2020.

WHO. Definitions and reporting framework for tuberculosis-2013 revision. Available at: Accessed on 20 September 2020.

Annual Tb report 2016. Available at: Accessed on 20 September 2020.

Janmeja A, Aggarwal D, Dhillon R. Analysis of treatment outcome in multi-drug resistant tuberculosis patients treated under programmatic conditions. Int J Res Med Sci. 2017;5:2401.

Nair D, Velayutham B, Kannan T, Tripathy J, Harries A, Natrajan M, et al. Predictors of unfavourable treatment outcome in patients with multidrug resistant tuberculosis in India. Public Health Action 2017;7:32-8.

Desai M, Jain K, Solanki R, Dikshit R. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2014;5:145.

TB India 2016, revised National Tb control programme, annual status report. Available at: Accessed on 20 September 2020.

Ahuja S, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J, et al. Multidrug resistant pulmonary tuberculosis treatment regimensand patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.

Kibret K, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug resistant tuberculosis under DOTS Plus: A systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6:7

Agarwalla A, Bhattacharya S, Dey A, Kar S, Chaudhuri AD. Study of outcome of management of MDR-TB cases under programmatic condition in India. J NTR Univ Health Sci. 2019;8:1-4.